" class="no-js "lang="en-US"> David M. Reese Archives - Medtech Alert
Saturday, March 25, 2023

Breaking News

Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa Celyad Oncology Appoints Georges Rawadi as Its New CEO Companion Spine Closes $60.1 Million Series A Funding Round EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

Sort by:

Date

Top Post

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease | MTA

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]

Read more

Diseases

 Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases | Pharmtech Focus

Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases

Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for […]

Cardiovascular

 FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia | Pharmtech Focus

FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha ® (evolocumab) as an […]

Industry News

 Amgen to Acquire Privately Held Teneobio for $900 Million in Cash With Future Contingent Milestone Payments | Pharmtech Focus

Amgen to Acquire Privately Held Teneobio for $900 Million in Cash With Future Contingent Milestone Payments

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a […]

Diseases

 Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA | Pharmtech Focus

Amgen Tezepelumab BLA Submitted to U.S. FDA

Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to […]

Drug Development

 FDA Accepts Amgen's Supplemental New Drug Application For Otezla ® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis | Pharmtech Focus

FDA Accepts Amgen's sNDA For Otezla ®

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for […]

  1. Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa

    Diseases

     Read more
  2. Celyad Oncology Appoints Georges Rawadi as Its New CEO

    Appointments

     Read more
  3. Companion Spine Closes $60.1 Million Series A Funding Round

    Fundraising

     Read more
  4. EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis

    News

     Read more
  5. Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer

    Appointments

     Read more